Tobam Has $4.41 Million Stake in DexCom, Inc. (NASDAQ:DXCM)

Tobam trimmed its stake in DexCom, Inc. (NASDAQ:DXCM) by 39.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 56,734 shares of the medical device company’s stock after selling 37,014 shares during the period. DexCom accounts for about 1.4% of Tobam’s investment portfolio, making the stock its 23rd largest position. Tobam’s holdings in DexCom were worth $4,412,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in DXCM. Versant Capital Management Inc bought a new position in shares of DexCom in the fourth quarter valued at approximately $25,000. Riverview Trust Co grew its stake in DexCom by 100.4% in the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after buying an additional 232 shares during the last quarter. Heck Capital Advisors LLC bought a new position in DexCom in the 4th quarter worth $38,000. RPg Family Wealth Advisory LLC acquired a new position in DexCom during the 3rd quarter worth $57,000. Finally, Covestor Ltd boosted its holdings in DexCom by 53.7% during the third quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock valued at $64,000 after acquiring an additional 335 shares during the period. 97.75% of the stock is currently owned by institutional investors and hedge funds.

DexCom Stock Down 0.5 %

DXCM opened at $88.32 on Friday. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00. The firm has a market cap of $34.50 billion, a price-to-earnings ratio of 52.89, a PEG ratio of 2.23 and a beta of 1.14. The firm’s 50-day simple moving average is $81.35 and its 200-day simple moving average is $75.69. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46.

Insiders Place Their Bets

In other news, EVP Jereme M. Sylvain sold 2,090 shares of the stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $181,641.90. Following the sale, the executive vice president now owns 83,526 shares in the company, valued at approximately $7,259,244.66. This represents a 2.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Kevin R. Sayer sold 33,359 shares of the company’s stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the transaction, the chief executive officer now owns 319,037 shares in the company, valued at approximately $27,727,505.67. This trade represents a 9.47 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 42,342 shares of company stock valued at $3,628,069. 0.30% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of equities analysts have recently commented on DXCM shares. Oppenheimer dropped their price objective on DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research note on Friday, October 25th. Redburn Atlantic upgraded DexCom from a “neutral” rating to a “buy” rating and upped their price target for the stock from $85.00 to $115.00 in a report on Monday. Citigroup raised their price objective on shares of DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Canaccord Genuity Group upped their target price on shares of DexCom from $89.00 to $99.00 and gave the company a “buy” rating in a research note on Monday, December 9th. Finally, Raymond James decreased their price target on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a research report on Friday, October 25th. Four analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, DexCom presently has a consensus rating of “Moderate Buy” and an average target price of $98.41.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.